Rheumatology has evolved from a therapeutic area with poor remission rates and reliance on broadly immunosuppressive treatment to approval of many targeted agents. Current rheumatology dynamics the REACH team is tracking include:
- First approvals in difficult to treat rheumatological conditions (e.g., Amgen’s Tavneos in GPA/MPA)
- Potential future approvals for groundbreaking technologies (e.g., Adipose-Derived Regenerative Cell Therapy for scleroderma and CAR T cell therapy for SLE)
- Increasing familiarity with and utilization of biosimilars
Search Rheumatology diseases we cover